• 한국의학물리학회지:의학물리
• /
• 제32권4호
• /
• pp.130-136
• /
• 2021

Purpose: The Halcyon radiotherapy platform at Groote Schuur Hospital was delivered with a factory-configured analytical anisotropic algorithm (AAA) beam model for dose calculation. In a recent system upgrade, the Acuros XB (AXB) algorithm was installed. Both algorithms adopt fundamentally different approaches to dose calculation. This study aimed to compare the dose distributions of cervical carcinoma RapidArc plans calculated using both algorithms. Methods: A total of 15 plans previously calculated using the AAA were retrieved and recalculated using the AXB algorithm. Comparisons were performed using the planning target volume (PTV) maximum (max) and minimum (min) doses, D95%, D98%, D50%, D2%, homogeneity index (HI), and conformity index (CI). The mean and max doses and D2% were compared for the bladder, bowel, and femoral heads. Results: The AAA calculated slightly higher targets, D98%, D95%, D50%, and CI, than the AXB algorithm (44.49 Gy vs. 44.32 Gy, P=0.129; 44.87 Gy vs. 44.70 Gy, P=0.089; 46.00 Gy vs. 45.98 Gy, P=0.154; and 0.51 vs. 0.50, P=0.200, respectively). For target min dose, D2%, max dose, and HI, the AAA scored lower than the AXB algorithm (41.24 Gy vs. 41.30 Gy, P=0.902; 47.34 Gy vs. 47.75 Gy, P<0.001; 48.62 Gy vs. 50.14 Gy, P<0.001; and 0.06 vs. 0.07, P=0.002, respectively). For bladder, bowel, and left and right femurs, the AAA calculated higher mean and max doses. Conclusions: Statistically significant differences were observed for PTV D2%, max dose, HI, and bowel max dose (P>0.05).

• 한국의학물리학회지:의학물리
• /
• 제21권3호
• /
• pp.298-303
• /
• 2010

전립선암에서 세기조절방사선치료와 입체조형방사선치료의 선량분포 특성을 비교하였다. 세기조절방사선치료에서는 치료계획표적용적에 200 cGy를 33회 조사하여 6,600 cGy가 조사되도록 하였다. 세기조절방사선치료에서는 PTV의 최대선량이 104.4%이었으며, 최소선량이 89.5%였으며, 삼차원입체조형치료에서는 PTV의 최대선량이 105.3%이었으며, 최소선량이 85.5%을 나타내었다. 100%에 대한 CI는 세기조절방사선치료에서 1.02였으며, 삼차원입체조형치료에서는 0.97을 나타내었다. 중요장기 직장에 대해서 세기조절방사선치료에서는 5,000 cGy 이상이 34.0%였으며, 삼차원입체조형치료에서는 63.3%였고, 방광에 대해서 세기조절방사선치료에서는 4,000 cGy 이상이 30.1%였으며, 삼차원입체조형치료에서는 30.6%였고, 오른쪽 대퇴골두부에 대해서 세기조절방사선치료에서는 2,000 cGy 이상이 9.5%였으며, 삼차원입체조형치료에서는 17.5%였고, 왼쪽 대퇴골두부에 대해서 세기조절방사선치료에서는 2,000 cGy 이상이 10.6%였으며, 삼차원입체조형치료에서는 18.3%을 나타내었다. 삼차원입체조형치료와 세기조절방사선치료의 비교에서 세기조절방사선치료가 삼차원입체조형치료에 비해 PTV의 선량분포에서는 5%의 정도 선량분포의 이득이 있었으며, 직장 선량에 대해서는 5,000 cGy 이상 선량에서 29.3%의 감소가 있었고, 방광 선량에 대해서는 거의 비슷한 분포를 나타내었고, 오른쪽 대퇴골두부의 선량에서는 8.0%, 왼쪽 대퇴골두부의 선량에서는 7.7%의 선량 이득을 나타내었다.

• 대한간호학회지
• /
• 제27권3호
• /
• pp.683-693
• /
• 1997

Urinary incontinence is defined as the involuntary and inappropriate loss of urine to failure to emit normal responses as the bladder fills, or inability to reach the bathroom in sufficient time. This study was undertaken to estimate the incidence of urinary incontinence and to determine the correlates of urinary incontinence among women. Subjects of this survey consisted of 408 women, 26 to 83 years old in Incheon. The results of this study are as follows. 1. Of the subjects 50.7% reported urine loss once or twice per year and 28.5% reported incontinence on a regular basis at least once per month. 2. 40.5% of women reported small volume accidents of only 1 to 2 drops, 31.4% ; 1 t-spoon, 16.9% : 1 T-spoon, while 10.1% of women couldn't estimate the volume of urine loss. 3. The volume of urine loss was great enough to require a change of garment (undergarments or outer garments) in 73%. But only 3.8% of those used some type of pads. 4. 56.5% of incontinent women didn't talk about their urinary incontinence with other persons because they felt that urinary incontinence was shameful(38.4%), was not a disease(31.6%), was incurable in spite of treatment(27.4%) and was fearful of being uncured (2.6%). 5. Only 15.5% of urinary incontinent women had sought treatment. 6. The incidence of urinary incontinence was significantly higher in women who had more pariety and uterine-ovarian disease, older age, worrying about where toilets were when they visited new places or voiding anxiety, nocturia and frequency, but was significantly lower in women who had coffee intake. The incidence of urinary incontinence was not related to smoking and enuresis. The results indicate that urinary incontinence is common among young and middle-aged women. That few seek treatment for urinary incontinence suggests a need for more information about women's attitudes toward urinary incontinence and more attention to this problem by health care providers.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권8호
• /
• pp.3365-3370
• /
• 2015

Radiotherapy has an important role in the treatment of prostate cancer. Three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) techniques are all applied for this purpose. However, the risk of secondary radiation-induced bladder cancer is significantly elevated in irradiated patients compared surgery-only or watchful waiting groups. There are also reports of risk of secondary cancer with low doses to normal tissues. This study was designed to compare received volumes of low doses among 3D-CRT, IMRT and VMAT techniques for prostate patients. Ten prostate cancer patients were selected retrospectively for this planning study. Treatment plans were generated using 3D-CRT, IMRT and VMAT techniques. Conformity index (CI), homogenity index (HI), receiving 5 Gy of the volume (V5%), receiving 2 Gy of the volume (V2%), receiving 1 Gy of the volume (V1%) and monitor units (MUs) were compared. This study confirms that VMAT has slightly better CI while thev olume of low doses was higher. VMAT had lower MUs than IMRT. 3D-CRT had the lowest MU, CI and HI. If target coverage and normal tissue sparing are comparable between different treatment techniques, the risk of second malignancy should be a important factor in the selection of treatment.

• Radiation Oncology Journal
• /
• 제38권1호
• /
• pp.60-67
• /
• 2020

Purpose: We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Materials and Methods: Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD_98%, DD_2% and DD_mean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. Results: The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DD_mean (%) for rectum and bladder. Conclusions: The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.

• 한국의학물리학회지:의학물리
• /
• 제33권4호
• /
• pp.121-128
• /
• 2022

Purpose: This study evaluated the quality of plans based on magnetic resonance-guided radiotherapy (MRgRT) tri-Co-60, linac, and conventional linac-based volumetric modulated arc therapy (linac-VMAT) for prostate cancer. Methods: Twenty patients suffering from prostate cancer with intermediate risk who were treated by MAT were selected. Additional treatment plans (primary and boost plans) were generated based on MRgRT-tri-Co-60 and MRgRT-linac. The planning target volume (PTV) of MRgRT-based plans was created by adding a 3 mm margin from the clinical target volume (CTV) due to high soft-tissue contrast and real-time motion imaging. On the other hand, the PTV of conventional linac was generated based on a 1 cm margin from CTV. The targets of primary and boost plans were prostate plus seminal vesicle and prostate only, respectively. All plans were normalized to cover 95% of the target volume by 100% of the prescribed dose. Dosimetric characteristics were evaluated for each of the primary, boost, and sum plans. Results: For target coverage and conformity, the three plans showed similar results. In the sum plans, the average value of V_65Gy of the rectum of MRgRT-linac (2.62%±2.21%) was smaller than those of MRgRT tri-Co-60 (9.04%±3.01%) and linac-VMAT (9.73%±7.14%) (P<0.001). In the case of bladder, the average value of V_65Gy of MRgRT-linac was also smaller. Conclusions: In terms of organs at risk sparing, MRgRT-linac shows the best value while maintaining comparable target coverage among the three plans.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권9호
• /
• pp.3945-3949
• /
• 2015

Background: For brachytherapy of cervical cancer, applicator shifts can not be avoided. The present investigation concerned Utrecht interstitial applicator shifts and their effects on organ movement and DVH parameters during 3D CT-based HDR brachytherapy of cervical cancer. Materials and Methods: After the applicator being implanted, CT imaging was achieved for oncologist contouring CTVhr, CTVir, and OAR, including bladder, rectum, sigmoid colon and small intestines. After the treatment, CT imaging was repeated to determine applicator shifts and OARs movements. Two CT images were matched by pelvic structures. In both imaging results, we defined the tandem by the tip and the base as the marker point, and evaluated applicator shift, including X, Y and Z. Based on the repeated CT imaging, oncologist contoured the target volume and OARs again. We combined the treatment plan with the repeated CT imaging and evaluated the change range for the doses of CTVhr D90, D2cc of OARs. Results: The average applicator shift was -0.16 mm to 0.10 mm for X, 1.49 mm to 2.14 mm for Y, and 1.9 mm to 2.3 mm for Z. The change of average physical doses and EQD2 values in Gy${\alpha}/{\beta}$ range for CTVhr D90 decreased by 2.55 % and 3.5 %, bladder D2cc decreased by 5.94 % and 8.77 %, rectum D2cc decreased by 2.94 % and 4 %, sigmoid colon D2cc decreased by 3.38 % and 3.72 %, and small intestines D2cc increased by 3.72 % and 10.94 %. Conclusions: Applicator shifts and DVH parameter changes induced the total dose inaccurately and could not be ignored. The doses of target volume and OARs varied inevitably.

• Radiation Oncology Journal
• /
• 제20권2호
• /
• pp.130-138
• /
• 2002

목적 : 근 침윤성 방광암에서 생존율에 영향을 주는 예후 인자를 분석하고 방사선 치료의 역할을 알아보고자 하였다. 대상 및 방법 : 1986년 1월부터 1998년 12월까지 전남대학교병원에서 근 침윤성 방광암으로 진단 받고 계획된 치료를 완료한 28명의 환자를 대상으로 후향적 분석을 시행하였다. 전체 28명 중 남자가 21명 여자가 7명이었으며 환자의 연령은 49세에서 84세까지 분포하였고 중앙값은 72세였다. 조직학적으로 모두 이행상피암으로 확진되었으며 grade 1은 1명, grade 2는 15명, grade 3는 9명, 불명인 경우가 3명이었다. 방사선치료는 선형가속기의 6 MV 또는 10 MV X-ray를 이용하였으며 일회선량은 1.8 내지 2.0 Gy로 3문 내지 4문 조사를 시행하였다. 투여된 총방사선량은 59 내지 66.6 Gy였고 중앙값은 61.24 Gy였다. 생존율은 Kaplan-Meier법으로 산출하였고 두 군간의 비교는 Log-rank test를 이용하였다. 생존율에 영향을 미치는 요인들을 Cox 비례위험모델로 다변량 분석하였다. 결과 : 생존율은 1, 2, 3, 5년에 각각 76, 46, 33, $33\%$로 나타났다. 중앙 생존 기간은 19개월이었다. 생존율에 영향을 미치는 가능성 있는 예후 인자로서 연령(70세 미만 대 이상), 성별, 당뇨병, 고혈압, 수신증 동반 여부, T-병기 (T3a 대 T3b 이상), TUR, 항암화학요법 여부, 방사선치료기간, 방사선량(60 Gy 미만 대 60 Gy 이상), 방사선치료반응정도를 분석에 포함시켰으며, 이들 중 단변량분석에서 T-병기(p=0.078)와 방사선량(p=0.051)이 통계학적 의의에 접근하였으며 방사선치료반응 정도(p=0.011)가 통계학적으로 의의 있게 나타났다. 그러나 다변량분석에서는 통계학적 의의를 가지는 인자가 없었다. 결론 : 근 침윤성 방광암에서 생존율에 미치는 예후 인자로 방사선량, 방사선치료반응 정도가 단변량분석에서 의미있게 나타났으나 다변량 분석에서는 확인되지 못하였으며 향후 더욱 많은 증례를 대상으로 이에 대한 전향적 무작위 임상 시험이 필요할 것으로 생각된다.

• Childhood Kidney Diseases
• /
• 제5권1호
• /
• pp.51-58
• /
• 2001

목 적 : 일차성 야뇨증의 치료는 민간 요법과 다양한 병인론에 근거한 각종 치료 방법이 개발 되어 있으나 가장 기본 치료인 야간 수분 제한의 치료 효과는 간과되어 왔다. 이에 저자들은 야뇨증의 일차적인 치료의 철저한 야간 수분 제한 효과만을 평가하고 성공 요인을 분석해 보고자 하였다. 대상 및 방법 : 1998년 10월부터 1999년 6월까지 이대목동병원 소아과 외래를 방문한 일차성 야뇨증 아동(주 3회 이상의 아뇨)중 2개월간의 야간 수분 제한에 순응도가 높은 41명(7.9${\pm}$2.3세)을 대상으로 하였다. 야간 수분 제한 전과 2개월 치료 후 매 2주마다 24시간 수분 섭취량과 요량을 (매주 1일이상) 기록하도록 하여 순응도를 평가하였다. 치료후 야뇨 횟수가 90$\%$이상 감소된 완전반응군, 50$\%$이상 9$\%$미만 감소된 부분반응군, 50$\%$이하로 감소된 무반응군으로 구분하여 치료율을 조사하였고, 치료에 대한 성공 요인으로 성별, 연령, 주간 배뇨 이상, 수분 섭취량, 요량, 최대 요량, 요농축능 등을 분석하였다. 치료 2개월 후 야간 요량, 최대 요량, 농축요삼투질 농도의 변화를 비교하였다. 결 과 : 야간 수분 제한 2개월 후의 반응률은 39.0$\%$ (l6/41)에서 완전반응, 43.9$\%$ (18/41)에서 부분반응, 17.1$\%$(7/41)에서 무반응을 보여 전체적으로 82.9$\%$ (34/41)에서 호전되었다. 야간 수분 제한의 치료 효과에 대한 예견 요인은 주간 배뇨 이상, 야간 수분 섭취량, 야간 요량, 방광 요인 등으로, 단증상 야뇨증 아동에서는 완전반응 50$\%$(13/26), 부분반응 46.2$\%$ (12/26)로 다증상 야뇨증 아동의 20$\%$ (3/15), 40$\%$ (6/15)에 비하여 유의하게 치료율이 높았다(P<0.05). 야간 수분 섭취량은 완전반응군 385${\pm}$109mL, 부분반응군 335${\pm}$105mL, 무반응군 233${\pm}$45 mL, 야간 다음은 각각 48.5$\%$(16/33), 42.4$\%$(14/33), 9.1$\%$(3/33)로 야간 수분 섭취량이 많을수록 유의하게 치료율이 높았다 (P<0.05). 야간 요량은 완전반응군 390${\pm}$62mL, 부분반응군 330${\pm}$136mL, 무반응군 140${\pm}$43mL, 야간 다뇨는 각각 59.3$\%$(16/27), 40.7$\%$(11/27), 0$\%$(0/27)로 야간 요량이 많을수록 유의하게 치료 효과가 좋았다(P<0.05). 일회 최대 요량은 완전반응군 236${\pm}$42 mL, 부분반응군 209${\pm}$56 mL, 무반응군 107${\pm}$36mL로 최대 요량이 많을수록 유의하게 치료 효과가 좋았다 (p<0.05). 연령, 성별, 일일 수분 섭취량, 다음, 일일 요량과 다뇨은 세 군간에 유의한 차이가 없었다. 야간 수분 섭취 제한 후 야간 요량의 감소 정도는 완전반응군 173${\pm}$56mL, 부분반응군 135${\pm}$83mL로 무반응군 28${\pm}$15mL에 비하여 유의하게 컸다 (P<0.05). 최대 요량의 증가도 완전반응군 88${\pm}$27mL, 부분반응군 79${\pm}$38mL로 무반응군 17${\pm}$13mL에 비하여 유의하게 컸다 (p<0.05). 농축요삼투질 농도의 증가 역시 완전반응군 190${\pm}$42mO느/kg, 부분반응군 254${\pm}$115mOsm/kg으로 무반응군 25${\pm}$32 mOsm/kg에 비하여 유의하게 컸다(p<0.05). 결 론 : 일차성 야뇨증은 야간 수분 섭취 제한만으로도 치료율이 높았고, 주간 배뇨 이상이 없고, 야간 다음, 야간 다뇨, 및 최대 방광용적이 높은 아동에서 치료 효과가 좋았다.

• Radiation Oncology Journal
• /
• 제37권1호
• /
• pp.43-50
• /
• 2019

Purpose: The aim of this retrospective study was to investigate the use of a radiopaque tissue fiducial marker (TFM) in the treatment of prostate cancer patients who undergo post-prostatectomy radiotherapy (PPRT). TFM safety, its role and benefit in quantifying the set-up uncertainties in patients undergoing PPRT image-guided radiotherapy were assessed. Materials and Methods: A total of 45 consecutive PPRT patients underwent transperineal implantation of TFM at the level of vesicourethral anastomosis in the retrovesical tissue prior to intensity-modulated radiotherapy. Prostate bed motion was calculated by measuring the position of the TFM relative to the pelvic bony anatomy on daily cone-beam computed tomography. The stability and visibility of the TFM were assessed in the initial 10 patients. Results: No postoperative complications were recorded. A total of 3,500 images were analysed. The calculated prostate bed motion for bony landmark matching relative to TFM were 2.25 mm in the left-right, 5.89 mm in the superior-inferior, and 6.59 mm in the anterior-posterior directions. A significant 36% reduction in the mean volume of rectum receiving 70 Gy (rV₇₀) was achieved for a uniform planning target volume (PTV) margin of 7 mm compared with the Australian and New Zealand Faculty of Radiation Oncology Genito-Urinary Group recommended PTV margin of 10 mm. Conclusion: The use of TFM was safe and can potentially eliminate set-up errors associated with bony landmark matching, thereby allowing for tighter PTV margins and a consequent favourable reduction in dose delivered to the bladder and rectum, with potential improvements in toxicities.